Integrated Genomic Analyses of Ovarian Carcinoma

Overview

Journal Nature

Specialty Science

Date 2011 Jul 2

PMID 21720365

Citations 4088

Affiliations

Soon will be listed here.

Abstract

A catalogue of molecular aberrations that cause ovarian cancer is critical for developing and deploying therapies that will improve patients' lives. The Cancer Genome Atlas project has analysed messenger RNA expression, microRNA expression, promoter methylation and DNA copy number in 489 high-grade serous ovarian adenocarcinomas and the DNA sequences of exons from coding genes in 316 of these tumours. Here we report that high-grade serous ovarian cancer is characterized by TP53 mutations in almost all tumours (96%); low prevalence but statistically recurrent somatic mutations in nine further genes including NF1, BRCA1, BRCA2, RB1 and CDK12; 113 significant focal DNA copy number aberrations; and promoter methylation events involving 168 genes. Analyses delineated four ovarian cancer transcriptional subtypes, three microRNA subtypes, four promoter methylation subtypes and a transcriptional signature associated with survival duration, and shed new light on the impact that tumours with BRCA1/2 (BRCA1 or BRCA2) and CCNE1 aberrations have on survival. Pathway analyses suggested that homologous recombination is defective in about half of the tumours analysed, and that NOTCH and FOXM1 signalling are involved in serous ovarian cancer pathophysiology.

Citing Articles

Establishment of a Novel In Vitro and In Vivo Model to Understand Molecular Carcinogenesis of Endometriosis-Related Ovarian Neoplasms.

Sohel H, Kiyono T, Zahan U, Razia S, Ishikawa M, Yamashita H Int J Mol Sci. 2025; 26(5).

PMID: 40076621 PMC: 11901000. DOI: 10.3390/ijms26051995.

Circulating Tumour DNA for Ovarian Cancer Diagnosis and Treatment Monitoring: What Perspectives for Clinical Use?.

Asante D, Tierno D, Grassi G, Scaggiante B Int J Mol Sci. 2025; 26(5).

PMID: 40076521 PMC: 11900478. DOI: 10.3390/ijms26051889.

A Rapid and Reliable Test for Promoter Hypermethylation in Paraffin Tissue Using Pyrosequencing.

Bacares R, Soslow R, Olvera N, Levine D, Zhang L Diagnostics (Basel). 2025; 15(5).

PMID: 40075848 PMC: 11898801. DOI: 10.3390/diagnostics15050601.

Predictive biomarkers for the efficacy of PARP inhibitors in ovarian cancer: an updated systematic review.

Wang Y, Allen I, Funingana G, Tischkowitz M, Joko-Fru Y BJC Rep. 2025; 3(1):14.

PMID: 40069561 PMC: 11897386. DOI: 10.1038/s44276-025-00122-9.

Learning directed acyclic graphs for ligands and receptors based on spatially resolved transcriptomic data of ovarian cancer.

Chowdhury S, Ferri-Borgogno S, Yang P, Wang W, Peng J, C Mok S Brief Bioinform. 2025; 26(2).

PMID: 40062614 PMC: 11891659. DOI: 10.1093/bib/bbaf085.

References

Carter H, Samayoa J, Hruban R, Karchin R . Prioritization of driver mutations in pancreatic cancer using cancer-specific high-throughput annotation of somatic mutations (CHASM). Cancer Biol Ther. 2010; 10(6):582-7. PMC: 3040948. DOI: 10.4161/cbt.10.6.12537. View

Bonome T, Levine D, Shih J, Randonovich M, Pise-Masison C, Bogomolniy F . A gene signature predicting for survival in suboptimally debulked patients with ovarian cancer. Cancer Res. 2008; 68(13):5478-86. PMC: 7039050. DOI: 10.1158/0008-5472.CAN-07-6595. View

Verhaak R, Hoadley K, Purdom E, Wang V, Qi Y, Wilkerson M . Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010; 17(1):98-110. PMC: 2818769. DOI: 10.1016/j.ccr.2009.12.020. View

Vaske C, Benz S, Sanborn J, Earl D, Szeto C, Zhu J . Inference of patient-specific pathway activities from multi-dimensional cancer genomics data using PARADIGM. Bioinformatics. 2010; 26(12):i237-45. PMC: 2881367. DOI: 10.1093/bioinformatics/btq182. View

Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun M . Cancer statistics, 2009. CA Cancer J Clin. 2009; 59(4):225-49. DOI: 10.3322/caac.20006. View

Farmer H, McCabe N, Lord C, Tutt A, Johnson D, Richardson T . Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005; 434(7035):917-21. DOI: 10.1038/nature03445. View

Keshava Prasad T, Goel R, Kandasamy K, Keerthikumar S, Kumar S, Mathivanan S . Human Protein Reference Database--2009 update. Nucleic Acids Res. 2008; 37(Database issue):D767-72. PMC: 2686490. DOI: 10.1093/nar/gkn892. View

Ahmed A, Etemadmoghadam D, Temple J, Lynch A, Riad M, Sharma R . Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. J Pathol. 2010; 221(1):49-56. PMC: 3262968. DOI: 10.1002/path.2696. View

Creighton C, Casa A, Lazard Z, Huang S, Tsimelzon A, Hilsenbeck S . Insulin-like growth factor-I activates gene transcription programs strongly associated with poor breast cancer prognosis. J Clin Oncol. 2008; 26(25):4078-85. PMC: 2654368. DOI: 10.1200/JCO.2007.13.4429. View

10.

Muggia F, Braly P, Brady M, Sutton G, Niemann T, Lentz S . Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study. J Clin Oncol. 2000; 18(1):106-15. DOI: 10.1200/JCO.2000.18.1.106. View

11.

Myatt S, Lam E . The emerging roles of forkhead box (Fox) proteins in cancer. Nat Rev Cancer. 2007; 7(11):847-59. DOI: 10.1038/nrc2223. View

12.

Schaefer C, Anthony K, Krupa S, Buchoff J, Day M, Hannay T . PID: the Pathway Interaction Database. Nucleic Acids Res. 2008; 37(Database issue):D674-9. PMC: 2686461. DOI: 10.1093/nar/gkn653. View

13.

Cuatrecasas M, Villanueva A, Matias-Guiu X, Prat J . K-ras mutations in mucinous ovarian tumors: a clinicopathologic and molecular study of 95 cases. Cancer. 1997; 79(8):1581-6. DOI: 10.1002/(sici)1097-0142(19970415)79:8<1581::aid-cncr21>3.0.co;2-t. View

14.

Chen H, Wang Y, Fann M . Identification and characterization of the CDK12/cyclin L1 complex involved in alternative splicing regulation. Mol Cell Biol. 2006; 26(7):2736-45. PMC: 1430317. DOI: 10.1128/MCB.26.7.2736-2745.2006. View

15.

Tothill R, Tinker A, George J, Brown R, Fox S, Lade S . Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res. 2008; 14(16):5198-208. DOI: 10.1158/1078-0432.CCR-08-0196. View

16.

Bookman M, Brady M, McGuire W, Harper P, Alberts D, Friedlander M . Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup. J Clin Oncol. 2009; 27(9):1419-25. PMC: 2668552. DOI: 10.1200/JCO.2008.19.1684. View

17.

Forbes S, Bhamra G, Bamford S, Dawson E, Kok C, Clements J . The Catalogue of Somatic Mutations in Cancer (COSMIC). Curr Protoc Hum Genet. 2008; Chapter 10:Unit 10.11. PMC: 2705836. DOI: 10.1002/0471142905.hg1011s57. View

18.

Esteller M, Silva J, Dominguez G, Bonilla F, Matias-Guiu X, Lerma E . Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J Natl Cancer Inst. 2000; 92(7):564-9. DOI: 10.1093/jnci/92.7.564. View

19.

Wiegand K, Shah S, Al-Agha O, Zhao Y, Tse K, Zeng T . ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med. 2010; 363(16):1532-43. PMC: 2976679. DOI: 10.1056/NEJMoa1008433. View

20.

McKusick V . Mendelian Inheritance in Man and its online version, OMIM. Am J Hum Genet. 2007; 80(4):588-604. PMC: 1852721. DOI: 10.1086/514346. View